These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 30405416)
61. Structure-activity relationship studies of resveratrol and its analogues by the reaction kinetics of low density lipoprotein peroxidation. Cheng JC; Fang JG; Chen WF; Zhou B; Yang L; Liu ZL Bioorg Chem; 2006 Jun; 34(3):142-57. PubMed ID: 16712899 [TBL] [Abstract][Full Text] [Related]
62. Evolution of kinase polypharmacology across HSP90 drug discovery. Antolin AA; Clarke PA; Collins I; Workman P; Al-Lazikani B Cell Chem Biol; 2021 Oct; 28(10):1433-1445.e3. PubMed ID: 34077750 [TBL] [Abstract][Full Text] [Related]
63. Activity profile relationships between structurally similar promiscuous compounds. Hu Y; Bajorath J Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530 [TBL] [Abstract][Full Text] [Related]
64. Insights into the Anti-inflammatory and Antiviral Mechanisms of Resveratrol. Chen X; Song X; Zhao X; Zhang Y; Wang Y; Jia R; Zou Y; Li L; Yin Z Mediators Inflamm; 2022; 2022():7138756. PubMed ID: 35990040 [TBL] [Abstract][Full Text] [Related]
65. The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Reyes-Parada M; Iturriaga-Vasquez P Expert Opin Drug Discov; 2016 Oct; 11(10):969-81. PubMed ID: 27552487 [TBL] [Abstract][Full Text] [Related]
66. A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology. Durrant JD; Amaro RE; Xie L; Urbaniak MD; Ferguson MA; Haapalainen A; Chen Z; Di Guilmi AM; Wunder F; Bourne PE; McCammon JA PLoS Comput Biol; 2010 Jan; 6(1):e1000648. PubMed ID: 20098496 [TBL] [Abstract][Full Text] [Related]
67. Updates to Binding MOAD (Mother of All Databases): Polypharmacology Tools and Their Utility in Drug Repurposing. Smith RD; Clark JJ; Ahmed A; Orban ZJ; Dunbar JB; Carlson HA J Mol Biol; 2019 Jun; 431(13):2423-2433. PubMed ID: 31125569 [TBL] [Abstract][Full Text] [Related]
68. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach. Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898 [TBL] [Abstract][Full Text] [Related]
69. Compound promiscuity: what can we learn from current data? Hu Y; Bajorath J Drug Discov Today; 2013 Jul; 18(13-14):644-50. PubMed ID: 23524195 [TBL] [Abstract][Full Text] [Related]
70. Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. Feldmann C; Yonchev D; Stumpfe D; Bajorath J Mol Pharm; 2020 Dec; 17(12):4652-4666. PubMed ID: 33151084 [TBL] [Abstract][Full Text] [Related]
71. A novel strategy for designing the magic shotguns for distantly related target pairs. Luo Y; Wang P; Mou M; Zheng H; Hong J; Tao L; Zhu F Brief Bioinform; 2023 Jan; 24(1):. PubMed ID: 36631399 [TBL] [Abstract][Full Text] [Related]
72. A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds. Schneider P; Schneider G Angew Chem Int Ed Engl; 2017 Sep; 56(38):11520-11524. PubMed ID: 28704574 [TBL] [Abstract][Full Text] [Related]
73. Polypharmacology of Berberine Based on Multi-Target Binding Motifs. Chu M; Chen X; Wang J; Guo L; Wang Q; Gao Z; Kang J; Zhang M; Feng J; Guo Q; Li B; Zhang C; Guo X; Chu Z; Wang Y Front Pharmacol; 2018; 9():801. PubMed ID: 30087614 [No Abstract] [Full Text] [Related]
74. The estrogenic activity of resveratrol: a comprehensive review of Qasem RJ Crit Rev Toxicol; 2020 May; 50(5):439-462. PubMed ID: 32744480 [No Abstract] [Full Text] [Related]
75. Ligand cluster-based protein network and ePlatton, a multi-target ligand finder. Du Y; Shi T J Cheminform; 2016; 8():23. PubMed ID: 27143991 [TBL] [Abstract][Full Text] [Related]
76. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Sumi NJ; Ctortecka C; Hu Q; Bryant AT; Fang B; Remsing Rix LL; Ayaz M; Kinose F; Welsh EA; Eschrich SA; Lawrence HR; Koomen JM; Haura EB; Rix U Cell Chem Biol; 2019 Sep; 26(9):1240-1252.e11. PubMed ID: 31257184 [TBL] [Abstract][Full Text] [Related]
77. Safety screening in early drug discovery: An optimized assay panel. Bendels S; Bissantz C; Fasching B; Gerebtzoff G; Guba W; Kansy M; Migeon J; Mohr S; Peters JU; Tillier F; Wyler R; Lerner C; Kramer C; Richter H; Roberts S J Pharmacol Toxicol Methods; 2019; 99():106609. PubMed ID: 31284073 [TBL] [Abstract][Full Text] [Related]
78. Comparative profiling of analog targets: a case study on resveratrol for mouse melanoma metastasis suppression. Chen X; Li W; Xu C; Wang J; Zhu B; Huang Q; Chen D; Sheng J; Zou Y; Lee YM; Tan R; Shen P; Wong YK; Lin Q; Wang J; Hua Z Theranostics; 2018; 8(13):3504-3516. PubMed ID: 30026862 [TBL] [Abstract][Full Text] [Related]
79. Polypharmacological Drugs in the Treatment of Epilepsy: The Comprehensive Review of Marketed and New Emerging Molecules. Kumari S; Mishra CB; Tiwari M Curr Pharm Des; 2016; 22(21):3212-25. PubMed ID: 26916017 [TBL] [Abstract][Full Text] [Related]